Company research / EOCN

Galmed Pharmaceuticals Ltd. (EOCN)

CIK 0001595353 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

43.7%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-09-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Stock splits: 1-for-15, first reflected in a filing dated 2023-08-09; 1-for-12, first reflected in a filing dated 2025-04-02; 1-for-8, first reflected in a filing dated 2026-09-02. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView